Clinical Trial Update: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating camrelizumab in combination with neoadjuvant chemotherapy for high-risk soft tissue sarcoma is ongoing, with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: UNKNOWN